Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

The president of one of the development partners called the groundbreaking an “important milestone,” while the fate of federal funding for other affordable projects is unknown.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth ...

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...

Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Analysts at Citi and Bank of America (NYSE:BAC) are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.

Only half of health insurer Cigna’s (NYSE:CI) clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company’s pharmacy benefits unit ...

An investigation by The Guardian finds the insurance giant UnitedHealth Group quietly paid thousands in bonuses to nursing home facilities that helped it gain Medicare enrollees and reduce ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...